Milbank LLP advised the sole dealer manager in connection with TriSalus Life Sciences, Inc.’s SEC-registered warrant exchange offer for common stock. TriSalus Life Sciences is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.
The Milbank deal team was led by Corporate Finance and Securities partner Brett Nadritch and associate Alex Becker.
